What the Sandoz CEO is thinking about the 2024 elections

Taking stock of the drug industry, from the lab to the medicine chest

October 15, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Photo illustration: STAT; Photo: Sandoz STAT+ | Opinion: What the Sandoz CEO is thinking about the 2024 elections Sandoz CEO Richard Saynor on how to reduce health care costs, stabilize supply chains, and ensure patient access to critical medicines. By Richard Saynor STAT+ | Jasper, looking to rival Genentech and Novartis' Xolair, reports positive data for skin condition drug The company is seeking to rival Genentech and Novartis' Xolair, a blockbuster that is already approved for chronic hives. By Jonathan Wosen Opinion: Why I'm wary of the new schizophrenia miracle drug The FDA has approved the first truly new antipsychotic in decades. But patients with schizophrenia have reasons to distrust the mental health care system. By Sally Littlefield

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser